


TAK-603

Cat. No.:	HY-120049
CAS No.:	158146-85-1
Molecular Formula:	C ₂₅ H ₂₆ N ₄ O ₆
Molecular Weight:	478.5
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	TAK-603 is a potent and orally active antirheumatic agent. TAK-603 inhibits Th1-type cytokine production. TAK-603 has the potential for the research of adjuvant arthritis ^{[1][2]} .
In Vitro	TAK-603 (0, 1, 10 μM; 48 h) suppresses the IFN-γ production but shows little effect on the IL-4 production in allo-reactive and an OVA-reactive BALB/c mouse T-cell line ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	TAK-603 (6.25 mg/kg; p.o.; daily) reduces the Th1-type cytokine production both in the arthritic lesion and in the spleen ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:	AA rats ^[2]
Dosage:	6.25 mg/kg
Administration:	P.o.; daily
Result:	Inhibited arthritic paw swelling with the inhibition rate of 65% and the IFN-γ mRNA expression in the arthritic joint was significantly reduced.

REFERENCES

[1]. Mizuno M, et al. Syntheses of metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603). Tetrahedron, 2006, 62(37), 8707-8714.

[2]. Ohta Y, et al. TAK-603 selectively suppresses Th1-type cytokine production and inhibits the progression of adjuvant arthritis. Immunology. 1997 Sep;92(1):75-83.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA